336 related articles for article (PubMed ID: 15867249)
1. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
2. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells.
Stover T; Kester M
J Pharmacol Exp Ther; 2003 Nov; 307(2):468-75. PubMed ID: 12975495
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
4. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
5. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo.
Zolnik BS; Stern ST; Kaiser JM; Heakal Y; Clogston JD; Kester M; McNeil SE
Drug Metab Dispos; 2008 Aug; 36(8):1709-15. PubMed ID: 18490436
[TBL] [Abstract][Full Text] [Related]
6. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
Latimer P; Menchaca M; Snyder RM; Yu W; Gilbert BE; Sanders BG; Kline K
Exp Biol Med (Maywood); 2009 Oct; 234(10):1244-52. PubMed ID: 19657067
[TBL] [Abstract][Full Text] [Related]
7. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure.
Frenkel V; Etherington A; Greene M; Quijano J; Xie J; Hunter F; Dromi S; Li KC
Acad Radiol; 2006 Apr; 13(4):469-79. PubMed ID: 16554227
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
10. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
11. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
12. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
13. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
14. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
15. High ceramide content liposomes with in vivo antitumor activity.
Shabbits JA; Mayer LD
Anticancer Res; 2003; 23(5A):3663-9. PubMed ID: 14666662
[TBL] [Abstract][Full Text] [Related]
16. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein.
Qi X; Chu Z; Mahller YY; Stringer KF; Witte DP; Cripe TP
Clin Cancer Res; 2009 Sep; 15(18):5840-51. PubMed ID: 19737950
[TBL] [Abstract][Full Text] [Related]
17. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.
Stover TC; Kim YS; Lowe TL; Kester M
Biomaterials; 2008 Jan; 29(3):359-69. PubMed ID: 17964645
[TBL] [Abstract][Full Text] [Related]
18. Synthetic, non-natural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice.
Qin JD; Weiss L; Slavin S; Gatt S; Dagan A
Cancer Invest; 2010 Jun; 28(5):535-43. PubMed ID: 20014940
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma.
Bruckheimer E; Harvie P; Orthel J; Dutzar B; Furstoss K; Mebel E; Anklesaria P; Paul R
Cancer Gene Ther; 2004 Feb; 11(2):128-34. PubMed ID: 14671672
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
